|
European Commission approves Kepivance(TM) (Palifermin) and U.S. BioDefense, Inc. Option Agreement with the University of Minnesota Ended.
Publication: M2 Presswire Publication Date: 31-OCT-05 |
|
|
|
How to access the full article: Free access to all articles is available courtesy of your local library. To access the full article click the "See the full article" button below. You will need your US library barcode or password.
|
|
|
COPYRIGHT 2005 Ingram Investment Ltd.
M2 PRESSWIRE-31 October 2005-US Financial Network: European Commission approves Kepivance(TM) (Palifermin) and U.S. BioDefense, Inc. Option Agreement with the University of Minnesota Ended(C)1994-2005 M2 COMMUNICATIONS LTD
RDATE:31102005
City of Industry, CA - Biotechnology industry news provided by Financial News USA (OTC: FNWU) Amgen (Nasdaq:AMGN), the world's largest biotechnology company, recently announced that Kepivance(TM) (palifermin) has received regulatory approval in the European Union (EU). Palifermin is now authorized in the EU to decrease the incidence, duration and severity...
Read the full article for free courtesy of your local library.
|
|
|
|
 |
| More Articles from M2 Presswire |
GeoTrust accelerates to UK SSL market leadership; Rapid issuance, comp...
October 31, 2005
|
Dot Hill reports third quarter 2005 results; Company meets revenue, ex...
October 31, 2005
|
University embarks on deep sea environmental project for BP.
October 31, 2005
|
For 20 years, Beaujolais Nouveau has been served on tables worldwide t...
October 31, 2005
|
TynTec introduce enterprise SMS industry standards New Quality of Serv...
October 31, 2005
|
|
| Find companies classified under Industrial organic chemicals not elsewhere classified |
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
